ClinicalTrials.gg
RecruitingNCT06898814IronHipUpdated Jun 1, 2026

The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery

A Phase 4 interventional study of Ferric Derisomaltose and Saline (NaCl 0,9 %) (placebo) in Hip Fracture and Anemia, sponsored by Soren Overgaard. Recruiting at 3 sites in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Soren Overgaard · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Hip Fractures with a site in Denmark — 8 open to participants now, 10 under way, none of them phase 3. Hip Fractures · Denmark.

Planned enrollment
14th of 45
210 · median 90
Started
2025
with 2 others
Phase 4
15 of 57
2 open now
Registered
53rd of 57
by date
Lead sponsor
2 of 57
Soren Overgaard

Among the 57 studies in Hip Fractures with a site in Denmark, this one is the 14th largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2025, is one of 15 in phase 4, and was the 53rd registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

8 of the 57 studies in Hip Fractures with a site in Denmark are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hip Fractures with a site in Denmark, or all of them as a file.
02

Study summary

The primary aim of this clinical trial is to investigate the effects of intravenous iron on recovery in mobility compared to the pre-fracture level in patients with a hip fracture

The main questions it aims to answer are:

It is hypothesize that intravenous iron will enhance gains in mobility and hereby recovery of mobility, increase hemoglobin (Hgb), lower fatigue, have a positive effect on skeletal muscles in the weeks and months after administration.

The primary objective is to compare the effect of a single dose of ferric derisomaltose (FDI) (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility, measured as the change from baseline in the New Mobility Score.

Participants will:

- Receive either a single dose of intravenous FDI (20 mg/kg body weight) (and saline) or placebo (saline) at 1-5 days after surgery.

This trial will be conducted at three hospitals in Denmark, involving an anticipated 210 participants.

03

Conditions studied

  • Hip Fracture
  • Anemia

Keywords

  • Hip fracture
  • Anemia
  • IV Iron
  • Mobility
  • Perioperative optimisation
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 65 years of age or older
  2. Acute proximal femur fracture surgery
  3. A measurement ≤6.5 mmol/L (10.5 g/dL) on day 1 to 5 postoperatively
  4. Independent prefracture indoor walking ability, indoor NMS ≥ 2
  5. Ability to speak and understand Danish
  6. Able to provide on the participants own behalf

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to intravenous iron
  2. Residing permanently at a nursing home
  3. Hematological conditions with a risk of iron overload e.g. haemochromatosis, hemosiderosis, or where alternative treatments are necessary e.g. haematological
  4. Other to iron treatment, e.g. severe liver cirrhosis and hepatitis
  5. Severe uncontrolled infection as assessed by the responsible clinician (e.g. bacteraemia or sepsis)
  6. Plasma sodium levels below 125 or above 150 mmol/L on the day of inclusion
  7. Renal replacement therapy
  8. Severe dementia assessed by physician
  9. Recent intravenous iron injection, 4 weeks prior to surgery
  10. Patient declared terminally ill
  11. Pathologic Fracture
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Active comparator
    Active Investigational Medicinal Product

    Drug: Ferric Derisomaltose

  • Placebo comparator
    Placebo

    Drug: Saline (NaCl 0,9 %) (placebo)

Interventions

  • DrugIron isomaltoside 1000Studies of Iron isomaltoside 1000Iron isomaltoside 1000 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The active intervention is a single dose of Ferric Derisomaltose, 20mg/kg body weight, diluted in 100 mL isotonic sodium chloride 0.9%

  • DrugSaline (NaCl 0,9 %) (placebo)

    Single dose of 100 mL isotonic sodium chloride 0.9%

06

What researchers measure

Primary outcomes

  1. New Mobility Score (NMS)

    The primary outcome is to compare the effect of a single dose of FDI (20 mg/kg body weight) relative to placebo on patients' recovery of functional mobility measured with New Mobility Score. New Mobility Score is a validated patient reported outcome measurement 0-9-point score for hip fracture patients, with 9 point equal to a fully independent indoor, outdoor and during shopping walking ability and 0 point, indicating no walking ability. Higher scores indicate a better outcome.

    Time frame: Measured as the change from baseline (reported as pre-fracture NMS) in the New Mobility Score after 4, 6 and 12 weeks

Secondary outcomes

  1. Hemoglobin

    Time frame: Measured at baseline, 6 and 12 weeks after intervention.

  2. Red blood cell transfusion requirement

    This will be measured by the proportion of patients who receive at least one red blood cell unit and the amounts of units per patient

    Time frame: Measured on postoperative day (POD) 7 and POD 30

  3. Fatigue, assessed using the Verbal Rating Scale for Fatigue (F-VRS)

    Fatigue will be assessed using the Verbal Rating Scale for Fatigue (F-VRS). This scale, ranging from 0 to 4, measures fatigue in hip fracture patients, where 0 indicates no fatigue and 4 represents extreme fatigue.

    Time frame: Measured at baseline, 4, 6 and 12 weeks after intervention.

  4. Quality of life with EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L )

    The EQ-5D-5L questionnaire measures health-related quality of life across five dimensions, with scores ranging from 1 (no problems) to 5 (extreme problems). Higher scores indicate worse outcomes, reflecting greater health issues.

    Time frame: Measured as a retrograde baseline the weeks prior to admission and at 6 and 12 weeks after intervention

  5. EuroQol Visual Analogue Scale (EQ VAS 0-100)

    The EQ VAS 0-100 (range) is a visual analogue scale where 0 represents the worst imaginable health state and 100 represents the best. Higher scores on the EQ VAS indicate a better health outcome.

    Time frame: Measured as a retrograde baseline the weeks prior to admission and at 6 and 12 weeks after intervention

  6. Fear of falls measured with, Short Falls Efficacy Scale International (Short-FES-I)

    Short Falls Efficacy Scale International (Short-FES-I) measures concern about falling during various activities, with scores ranging from 7 (no concern about falling) to 28 (severe concern about falling). Higher scores indicate greater concern about falling.

    Time frame: Measured at baseline and at 6 and 12 weeks after intervention.

  7. 30 second Sit-to-Stand-Test (STS)

    Participants are encouraged to stand and fully sit as many times as possible within 30 seconds, with correct form monitored by the tester. If a participant uses their arms, they score a 0, and only correctly executed stands are counted. This test assesses a wide range of ability levels. Lower score indicates worse outcome.

    Time frame: Measured at baseline, 6 and 12 weeks

  8. Activity of daily living, asessed with Barthel Index 20

    Barthel 20 Index measures a patient's level of independence in daily activities, with scores ranging from 0 (complete dependence) to 20 (complete independence). Higher scores indicate a better outcome, reflecting greater independence.

    Time frame: Measured as a retrograde baseline and at 6 and 12 weeks after intervention

  9. Pain, assessed using the Verbal Rating Scale for pain

    Hip fracture-related pain will be assessed using the Verbal Rating Scale for Pain, which ranges from 0 to 4. A score of 0 indicates no pain, while a score of 4 represents unbearable or the worst imaginable pain

    Time frame: Measured at baseline and at 6 and 12 weeks after intervention

  10. Days alive and at home up to 30 (DAH30)

    The DAH30 is determined using a combination of electronic medical records (obtaining length of stay) and direct participant inquiries at the 6 week follow up

    Time frame: Measured at 6 weeks after intervention.

  11. Serious adverse event (SAE)

    SAE defined following the ICH - GCP guidelines

    Time frame: Will be assessed up to the 6 weeks follow up

  12. Mortality

    The time of death is determined using validated registry-based data, from which survival rates, as well as 30-day and 90-day mortality rates, are calculated.

    Time frame: 90 days

Other outcomes

  1. A. Cost-effectiveness analysis

    Explorative outcome A: Cost-effectiveness analysis will be made from a societal perspective including cost of FDI, hospital bed days, readmissions, outpatient visits and costs related to lost productivity of the patients (production loss). The analysis will be done according to the guidelines for health economic evaluation. The analysis will be based on data from the electronic patient records and data on the duration of patient's sick leave and absence from work from patient surveys. The main results from the analysis will be a comparison of the mean costs per patient in the intervention and the control group, the mean change in Quality Adjusted Life Years gained in the two groups (based on EQ5D) and the incremental cost-effectives ratio.

    Time frame: 90 days post intervention

  2. B. Physical Activity

    Explorative outcome B: This outcome focuses on evaluating the effect of intravenous iron on 24-hour physical activity of patients. Physical activity will be measured using the SENS motion activity monitor. Each participant will wear the monitor for 10 days starting at the 6-week follow-up, measuring their time spent lying, sitting, standing, walking, and transitioning between these states. After 10 days, the monitor will be collected, and data will be analyzed to compare the combined amount of time spent standing and walking between the two groups. This outcome will be measured on the participants enrolled at Bispebjerg Hospital.

    Time frame: SENS motion activity monitor measurements will be collected 10 days after the 6-week follow-up.

  3. C. Hand Grip Strength

    Explorative outcome C: Hand grip strength will be assessed using a dynamometer measured in kilograms with a higher score representing better hand grip strength. Measured on participants enrolled at Bispebjerg Hospital. This outcome aims to determine how intravenous iron therapy influences hand grip strength, comparing the changes between the two groups.

    Time frame: Hand grip strength will be measured at baseline and again at the 6- and 12-week follow-ups.

  4. D. Knee Extension Strength

    Explorative outcome D: Knee extension strength will be measured using a dynamometer, measured in Nm/Kg with a higher score representing better Knee extension strength. Measured on participants enrolled at Bispebjerg Hospital. The goal is to examine the effect of intravenous iron therapy on knee extension strength between the two groups at these key points.

    Time frame: Knee extension strength will be measured at baseline and at 6- and 12-week follow-ups.

  5. E. Cognition assessed using, Orientation-Memory-Concentration test (OMC)

    Exploratory Outcome E: Cognition will be assessed using the Orientation-Memory-Concentration (OMC) test to examine potential differences between the groups. The OMC test range from 0-28 points, with a score of 25-27 indicating no or minimal cognitive impairment, and a score of 0-7 indicating severe impairment.

    Time frame: Measured at baseline, week 6 and 12 post-intervention.

  6. F. Ferritin Levels as a Measure of Iron Status

    Exploratory Outcome F: This outcome focuses on assessing the ferritin levels in both the intervention and placebo groups. Ferritin will be measured in ng/mL. The aim is to determine how intravenous iron therapy affects ferritin levels in comparison to the placebo group.

    Time frame: Measured at baseline and week 6 and 12 post intervention.

  7. G: Transferrin Saturation as a Measure of Iron Status

    Explorative outcome G: Transferrin saturation, measured as a percentage, will be assessed in both the intervention and placebo groups. This outcome will evaluate how transferrin saturation is affected by intravenous iron therapy compared with placebo.

    Time frame: Transferrin saturation will be measured at baseline, and at the 6- and 12-week follow-ups.

07

Study locations

2 of 3 sites recruiting
  • Department of Orthopedic Surgery and Traumatology, Bispebjerg, Copenhagen University Hospital
    Copenhagen NV, 2400, Denmark
    Active, not recruiting

    Not enrolling at this site.

  • Department of Orthopedic Surgery and Traumatology, Herlev, Copenhagen University Hospital
    Herlev, 2730, Denmark
    Recruiting
  • Department of Orthopaedic Surgery, Odense and Svendborg University Hospital
    Odense C, 5000, Denmark
    Recruiting
08

References and documents

Publications

  • Jones NT, Kristensen MT, Christensen R, Alva-Jorgensen JP, Berger AL, Eggertsen MA, Bang Foss N, Henriksen M, Jensen TG, Kidholm K, Lunn TH, Nielsen MS, Palm H, Petersen PB, Stampe H, Viberg B, Overgaard S, Aasbrenn M. The effects of intravenous iron on mobility in older adults following hip fracture surgery: protocol for a multicentre, parallel group, randomised controlled trial - the IronHip trial. BMJ Open. 2026 Jul 13;16(7):e121250. doi: 10.1136/bmjopen-2026-121250. PubMed 42442814 ↗

Individual participant data

Plan to share: Yes — Access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), will be provided to anyone who wishes to access the data.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Immediately following publication, no end date.

Access criteria: Any researcher, affiliated to an established institution

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 33 non-industry phase 4 interventional studies under Hip Fractures, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 23 months is close to that.

Counting every sponsor, half of 33 studies reached it within 25 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2025
First posted
Mar 27, 2025
StartActual
Jun 9, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Sep 14, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06898814
Lead sponsor
Soren Overgaard
Collaborators
University Hospital Bispebjerg and Frederiksberg, Copenhagen University Hospital at Herlev, Odense University Hospital, Musculoskeletal Statistics Unit, The Parker Institute, Svendborg Hospital
Responsible party
Soren Overgaard (Clinical Professor, DMSc, University Hospital Bispebjerg and Frederiksberg) — Sponsor-investigator
First posted
Mar 27, 2025
Start date
Jun 9, 2025
Primary completion
Jun 1, 2027 (estimated)
Completion
Sep 14, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Nicolas Tekin Jones, MD
Contact
nicolas.tekin.jones@regionh.dk
+4520491890
Søren Overgaard, MD, DMSc
Contact
soeren.overgaard@regionh.dk
Nicolas Tekin Jones, MD
principal investigator · Copenhagen University Hospital Bispebjerg, Department of Orthopaedic Surgery and Traumatology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion